Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 8,146 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period 1 Clear all

Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions: Lenalidomide, Velcade; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: CE/BZA, Itraconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 64 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Hypertension
Interventions: Irbesartan, Avapro; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Dental Caries
Interventions: Test Dentifrice, Reference Dentifrice, Negative Control Dentifrice; Drug
Lead sponsor: HALEON; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pelvic Pain
Interventions: Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 35 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of
Interventions: glecaprevir/pibrentasvir (GLE/PIB); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diabetes Mellitus, Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Natriuretic Peptides, Metabolism, Energy Expenditure
Interventions: Sacubitril, Valsartan 97-103 mg Oral Tablet, Valsartan 160 mg, Intravenous Glucose Tolerance Test, Standardized Meals, Exercise capacity VO2 maximum determination; Drug · Other · Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Squamous Cell Carcinoma, Skin Cancer, Keratoacanthoma, Cutaneous Tumor, Skin Cancer, Squamous Cell, Lesion Skin
Interventions: Injection of TVEC into target lesions - week 1-2, Injection of TVEC into target lesions 3wks after 1st injection, Injection of TVEC into target lesions 2wks after 2nd injection, Injection of TVEC into target lesions 2wks after 3rd injection; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Scottsdale, Arizona • Tucson, Arizona

Conditions: Lung Cancer, Head and Neck Cancer
Interventions: Panobinostat (LBH589), erlotinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy
Interventions: ABT-126, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Schizophrenia
Interventions: AZD8529, Placebo to match AZD8529; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity, Overweight
Interventions: Confident Moves (CM) Intervention; Behavioral
Lead sponsor: Iowa State University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Des Moines, Iowa

Conditions: Bipolar Disorder
Interventions: Lamotrigine; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 10 Years to 20 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 1 Diabetes Mellitus
Interventions: iBOLUSED; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Neuromyelitis Optica Spectrum Disorder
Interventions: Ravulizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Miami, Florida • Boston, Massachusetts + 2 more

Conditions: Heart Failure
Interventions: LCZ 696, Placebo, Para-aminohippurate, Iohexol, Aprepitant; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Advanced Parkinson's Disease
Interventions: Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube; Drug · Device
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 30 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 31
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 25 more

Conditions: Major Depressive Disorder
Interventions: Placebo, Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 819 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 39
States / cities: Garden Grove, California • National City, California • Oceanside, California + 34 more

Conditions: Fragile X Syndrome
Interventions: Acamprosate, Lovastatin, Minocycline, Placebo, Baclofen; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 15 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Sedentary Lifestyle, Self Efficacy, Control Locus, Aging
Interventions: App Experimental condition, App Condition Control; Behavioral
Lead sponsor: Brandeis University; Other
Eligibility: 50 Years and older
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Pneumonia, Cancer, Acute Leukemia
Interventions: Ribavirin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Vasomotor Symptoms
Interventions: Acupuncture; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: Hyperlipidemia
Interventions: MCT oil + Butter in Coffee; Dietary Supplement
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colorectal Cancer
Interventions: 5-Fluorouracil, Leucovorin, Capecitabine [Xeloda]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 14 more

Search by objective public record fields.

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women

Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions

A Clinical Study to Assess an Experimental Dentifrice in an Experimental Model of Early Stage Caries

Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment

Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor

NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals

Study of TVEC in Patients With Cutaneous Squamous Cell Cancer

Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers

Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in Healthy Volunteers

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

Confident Moves Intervention Efficacy Trial: Obesity Care Settings

Lamotrigine Monotherapy in Pediatric Bipolar Disorder

Evaluation of a Simulation-Based Educational Tool for Personalized Feedback in Insulin Therapy Management

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

Neurophysiological and Acute Pharmacological Studies in FXS Patients

Increasing Physical Activity Among Sedentary Older Adults:What, Where, When, and With Whom

Respiratory Syncytial Virus - RSV Protocol

Acupuncture in Menopause

Effect of Butter & MCT Oil on Lipoproteins - A RCT

A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer